GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	NT$25.20	-1.75%	161,868
08/07/26	NT$25.65	-0.58%	189,707
07/07/26	NT$25.80	-2.09%	423,083
06/07/26	NT$26.35	+3.33%	653,130
03/07/26	NT$25.50	+0.79%	260,868

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 09/07/2026			5-day change	1st Jan Change
25.20 ^TWD	-1.75%		+0.20%	-2.14%

06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.84B 88.27M 77.42M 71.48M 66.05M 125M 8.45B 128M 859M 334M 4.14B 331M 324M 14.36B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.62B 81.43M 71.43M 65.94M 60.94M 115M 7.8B 118M 793M 308M 3.82B 306M 299M 13.25B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-14	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
14/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
28/05/25	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 day	-1.75%
1 week	+0.20%
Current month	-1.56%
1 month	+0.40%
3 months	+8.86%
6 months	-2.51%
Current year	-2.14%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	25.1	26.7
1 month	24.6	30
Current year	22.1	30
1 year	20.55	30
3 years	15.6	32.9
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Kao Chung Tsai BRD	Director/Board Member	64	-
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-1.75%	+0.20%	+4.56%	-19.49%	89.85M
LONZA GROUP AG	+1.68%	+3.19%	+3.55%	+10.22%	49.42B
REVOLUTION MEDICINES, INC.	+1.49%	+1.43%	+398.29%	+605.40%	40.34B
IQVIA HOLDINGS INC.	+2.36%	+0.52%	+28.45%	-5.16%	34.01B
BEONE MEDICINES AG	+0.61%	+2.03%	+18.77%	+57.73%	33.56B
CELLTRION, INC.	-2.09%	-0.80%	+3.56%	+33.56%	26.84B
ASCENDIS PHARMA A/S	+0.42%	+1.41%	-	-	17.22B
MEDPACE HOLDINGS, INC.	+0.73%	-4.58%	+65.78%	+120.05%	15.19B
IONIS PHARMACEUTICALS, INC.	-22.73%	-19.97%	+52.85%	+56.69%	13.96B
EUROFINS SCIENTIFIC SE	+2.59%	-0.49%	+15.24%	+20.83%	13.36B
Average	-1.66%	+0.63%	+65.67%	+97.76%	24.4B
Weighted average by Cap.	-0.32%	+0.90%	+87.65%	+134.42%

	2024	2025
Net sales	14.7M 458K 401K 371K 342K 649K 43.82M 662K 4.46M 1.73M 21.44M 1.72M 1.68M 74.44M	37.86M 1.18M 1.03M 954K 882K 1.67M 113M 1.71M 11.47M 4.46M 55.23M 4.43M 4.33M 192M
Net income	-230M -7.15M -6.27M -5.79M -5.35M -10.14M -685M -10.35M -69.61M -27.05M -335M -26.85M -26.27M -1.16B	-235M -7.32M -6.42M -5.93M -5.48M -10.39M -701M -10.59M -71.29M -27.7M -343M -27.5M -26.9M -1.19B
Net Debt	-442M -13.76M -12.07M -11.15M -10.3M -19.52M -1.32B -19.91M -134M -52.06M -645M -51.69M -50.55M -2.24B	-220M -6.84M -6M -5.54M -5.12M -9.7M -655M -9.89M -66.58M -25.87M -320M -25.68M -25.12M -1.11B